Decision-making experiences of patients and partners opting for active surveillance in esophageal cancer treatment

Research output: Contribution to journalArticleAcademicpeer-review

4 Downloads (Pure)

Abstract

Objectives: 

This study explored the decision-making experiences of patients and their partners or primary caregiver who opted for experimental active surveillance (instead of standard surgery) for the treatment of esophageal cancer. 

Methods: 

Seventeen couples participated. Semi-structured interviews were conducted on couples’ joint experiences as well as their individual experiences. Preferred and perceived role in the treatment decision-making process was assessed using the adjusted version of the Control Preferences Scale, and perceived influence on the treatment decision was measured using a visual analog scale. 

Results: 

Couples reflected on the decision-making process as a positive collaboration, where patients retain their autonomy by making the final decision, and partners offer emotional support. Couples reported about an overwhelming amount and sometimes conflicting information about treatments among different hospitals and healthcare providers. 

Conclusions: 

Patients often involve their partner in decision-making, which they report to have enhanced their ability to cope with the disease. The amount and sometimes conflicting information during the decision-making process provide opportunities for improvement. Practice implications: Couples can benefit from an overview of what they can expect during treatment course. If active surveillance becomes an established treatment option in the future, provision of such overviews and consistent information should become more streamlined.

Original languageEnglish
Article number108361
JournalPatient Education and Counseling
Volume127
DOIs
Publication statusPublished - Oct 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors

Fingerprint

Dive into the research topics of 'Decision-making experiences of patients and partners opting for active surveillance in esophageal cancer treatment'. Together they form a unique fingerprint.

Cite this